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Kinase assays. Inhibitor (20 µl, 15% DMSO in H2O) was introduced to a solution 
containing CAK-activated CDK2/cyclinA (20 µl, 0.3 mg/ml, 80 mM Tris, pH 7.2, 40 
mM MgCl2) in a 96-well microtiter array. The kinase reaction was initiated by the 
addition of substrate histone H1, ATP mixture (20 µl, 0.22 mg/mL histone H1, 10 mM 
HEPES, pH 7.2, 45 µM ATP, 150 µg/ml BSA, 1.5 mM DTT, 0.1 vol % [γ-32P]ATP, 10 
µCi/mL). After 30 minutes, the reaction mixtures were transferred to a 96-well dot-
blot apparatus and quenched by the addition of 35 µl of 10% TCA. The 
phosphorylated histone H1 was immobilized onto a nitrocellulose membrane, 
washed with 10% TCA followed by H2O, and quantitated by densitometry on a 
phosphoimager. Starfish cdc2/cyclinB (which is the major source for isolating this 
kinase) was purified by affinity chromatography as described [J. Vesely et al., Eur. J. 
Biochem. 224, 771 (1994)]. Kinase assays were perfomed in the presence of 1 
mg/ml hisone H1 (Sigma type III-S), 15 µM [γ-32P]ATP (1 mCi/ml), in a final volume 
of 30 µL. After 10 minutes at 30ºC, 25-µl aliquots were spotted onto 2.5 cm x 3 cm 
pieces of phosphocellulose (Whatman P81), and after 20 s the filters were washed 
five times with dilute acid (1 ml phosphoric acid/100 ml H2O). The filters were 
transferred into 2 ml of ACS (Amersham) scintillation fluid and counted.  
Immunoprecipitations and kinase assays. Cells were grown to mid-log phase in rich media. Frozen cell pellets 
(~120 OD600) were resuspended in lysis buffer (25 mM HEPES-NaOH pH 7.5, 250 mM NaCl, 0.2% Triton X-100, 
5 mM ß-glycerolphosphate, 5 mM NaF, 10% glycerol, 1 mM EDTA, 1 mM DTT, 1 µg/ml leupeptin, 1 µg/ml 
pepstatin A, 10 mTIU/ml aprotinin, 1 mM PMSF) and lysed by mechanical disruption in a Beadbeater (Biospec). 
Lysates were clarified by centrifugation for 15 minutes at 14,000g and protein content assessed with the BioRad 
protein assay method (BioRad). A total of 400 µl of pA:sepharose (Sigma) and 40 µg of mAb12CA5 (BAbCo), 
which binds to the HA epitope present at the COOH-termini of the CDKs, were added to 20 mg of crude lysate 
and rotated for 1 hour at 4ºC. The beads were then washed twice with HBST (10 mM HEPES-NaOH pH 7.5, 150 
mM NaCl, 0.2% Triton X-100) and twice with HBS (10 mM HEPES pH 7.5, 150 mM NaCl) and then distributed 
evenly into 40 tubes. Next, 1 µl of inhibitor (1 µM to 10 mM) or DMSO was added to 20 µl of kinase assay buffer 
(10 mM HEPES-NaOH pH 7.5, 150 mM NaCl, 10 mM MgCl2, 20 µM ATP, 2 µCi [γ-32P]ATP), which included 5 µg 
of histone H1 for Cdc28 assays, 2 µg of Pho4 for PHO85 assays, or 2.5 µg of GST-CTD for Srb10 and Kin28 
assays. This mixture was added to the washed beads, incubated for 15 minutes at room temperature, and 
stopped by the addition of 4x stop buffer [250 mM Tris pH 6.8, 40% (v/v) glycerol, 20% (v/v) ß-mercaptoethanol, 
9.2% SDS, 0.04% bromophenol blue]. Reaction products were analyzed by SDS-PAGE. Incorporation of 32P into 
substrates was quantified by excising the substrate from dried gels and measuring Cerenkov radiation in a 
scintillation counter.  
Yeast strains. To epitope tag yeast CDKs, a W303 strain (MATa ura3-52 leu2-3112 trp1-1 his3-11 ade2-1 can1-
100) was transformed with an integrating plasmid [P. Hieter, R.S. Sikorski, Genetics, 122, 19 (1989)] containing a 
5' fragment of a yeast CDK fused to a hemagglutinin tag (underlined) followed by the ACT1 terminator. 
YIpFHE83 contained a 744-bp fragment of the CDC28 coding region and altered the COOH-terminus of Cdc28 
from QES to QESMAYPYDVPDYASLGPGP. YIpJC01 contained a 866-bp fragment from the KIN28 coding 
region and altered the COOH-terminus of Kin28 from IRN to IRTMAYPYDVPDYASLGPGP. YIpFHE48 contained 
a 667-bp fragment of the PHO85 coding region and altered the COOH-terminus of Pho85 from HAS to 
HASMAYPYDVPDYASLGPGP. YIpFHE101 contained a 1097-bp fragment from the SRB10 coding region and 
altered the COOH-terminus of Srb10 from NRR to NRTMAYPYDVPDYASLGPGP.  
Library design. The following table indicates the structures of representative compounds used in this study. 
These compounds were synthesized on solid support (using either polystyrene resin or Chiron pins [H.M. Geysen 
et al., Immunol. Methods 102, 259 (1987)] or in solution. The solid phase chemistry has been described [N. S. 
Gray et al., Tetrahedron Lett. 38, 1161 (1997); T. C. Norman et al., J. Am. Chem. Soc. 118, 7430 (1996)] and the 




Crystallization and structure determination. Human CDK2 was purified and crystallized as previously 
described [J. Rosenblatt et al., J. Mol. Biol. 230, 1317 (1993)]. Crystals were soaked with purvalanol B in a 
solution containing 1% DMSO and 5 % ethyleneglycol, necessary to solubilize the compound. A procedure 
involving chemical crosslinking was employed to prevent crystals from cracking. The crystals were first soaked in 
a solution containing 0.5 mM ATP, 1 mM MgCl2 for 2 hours, then crosslinked with 0.1% glutaraldehyde for 1 hour 
at 4ºC. After extensive washing the crystals were transferred to an inhibitor solution in 200 mM HEPES, 5% 
ethyleneglycol and 1% DMSO. This procedure allowed crystals to be soaked at inhibitor concentrations up to 0.2 
mM for several days without showing any damage. X-ray data collection was carried out on an R-Axis II image 
plate detection system, mounted on a Rigaku rotation-anode generator. Data were collected under a stream of 
cold nitrogen (100 K) from a single crystal in 25% ethyleneglycol. The CDK2-purvalanol B crystals diffracted as 
well as native, although freezing altered slightly the unit cell dimensions and increased the mosaic spread from 
0.2º to 0.6º. The crosslinking itself did not alter the diffraction characteristics significantly. Intensity data were 
processed with the programs DENZO and SCALEPACK [Z. Otwinowski and W. Minor, Methods Enzymol. 276, 
307 (1997)]. The program TRUNCATE, as implemented in the CCP4 suite [Acta Crystallogr. D50, 760 (1994)], 
was used to obtain the final set of structure factor amplitudes. Refinement of the CDK2-purvalanol B complex 
was started from the coordinates of the highly refined CDK2-ATP model. All refinement steps were carried out 
with the program X-PLOR (A. T. Brünger, Yale Univ. Press, Version 3.0, 1991). Molecular replacement followed 
by rigid body refinement was necessary to succesfully reorient and reposition the CDK2 molecule in the unit cell 
of the frozen crystal. The CDK2 model was further refined by several rounds of conjugated-gradient energy 
minimization. At this stage the electron density corresponding to purvalanol B was clearly visible from 2Fo-Fc and 
Fo-Fc Fourier maps and the inhibitor could be added to the model. Several rounds of both x-ray restrained energy 
minimization and molecular dynamics in the resolution range 7 to 2.05 Å, alternated with model building with the 
program O [T. A. Jones amd M. Kjeldgaard, Acta Crystallogr. A47, 110 (1991)], were necessary to improve the 
model. In the last rounds of refinement low resolution data were included by applying a bulk solvent correction [J. 
S. Jiang and A. T. Brünger, J. Mol. Biol. 243, 100 (1994)]. At this point a simulated annealing omit map [A. Hodel 
et al., Acta Crystalogr. A48, 851 (1992)] of the inhibitor binding site indicated that a minor portion of the 
purvalanol B molecules was bound with its aniline ring flipped ~160º (based on electron density for the 3-
chloroanilino atom). The double conformation of purvalanol B was included in the refinement, lowering the Rfree 
by 0.5%. The final model includes 279 residues of CDK2 (residues 36-43 and 153-163 are not included because 
of weak or missing electron density), purvalanol B, 91 water molecules, and one molecule of ethyleneglycol. 
Contact surfaces were calculated with program MS [J. Appl. Crystallogr. 16, 548 (1983)] by using standard 
VDW's radii and a probe radius of 1.7 Å. 
